

**AMENDMENT IN THE NATURE OF A SUBSTITUTE
TO H.R. 1157
OFFERED BY MRS. MYRICK OF NORTH CAROLINA**

Strike all after the enacting clause and insert the following:

1 SECTION 1. SHORT TITLE.

2 This Act may be cited as the “Breast Cancer and
3 Environmental Research Act of 2008”.

**4 SEC. 2. EXPANDING COLLABORATIVE RESEARCH ON
5 BREAST CANCER AND THE ENVIRONMENT.**

6 (a) IN GENERAL.—Subpart 1 of part C of title IV
7 of the Public Health Service Act (42 U.S.C. 285 et seq.)
8 is amended by adding at the end the following:

9 **“SEC. 417F. INTERAGENCY BREAST CANCER AND ENVIRON-
10 MENTAL RESEARCH COORDINATING COM-
11 MITTEE.**

12 **“(a) INTERAGENCY BREAST CANCER AND ENVIRON-
13 MENTAL RESEARCH COORDINATING COMMITTEE.—**

14 **“(1) ESTABLISHMENT.—**Not later than 6
15 months after the date of the enactment of this sec-
16 tion, the Secretary shall establish a committee, to be
17 known as the Interagency Breast Cancer and Envi-

1 ronmental Research Coordinating Committee (in this
2 section referred to as the ‘Committee’).

3 “(2) DUTIES.—The Committee shall—

4 “(A) share and coordinate information on
5 existing research activities, and make rec-
6 ommendations to the National Institutes of
7 Health and other Federal agencies regarding
8 how to improve existing research programs,
9 that are related to breast cancer research;

10 “(B) develop a comprehensive strategy and
11 advise the National Institutes of Health and
12 other Federal agencies in the solicitation of pro-
13 posals for collaborative, multidisciplinary re-
14 search, including proposals to evaluate environ-
15 mental and genomic factors that may be related
16 to the etiology of breast cancer that would—

17 “(i) result in innovative approaches to
18 study emerging scientific opportunities or
19 eliminate knowledge gaps in research to
20 improve the research portfolio;

21 “(ii) outline key research questions,
22 methodologies, and knowledge gaps;

23 “(iii) expand the number of research
24 proposals that involve collaboration be-
25 tween 2 or more national research insti-

1 tutes or national centers, including pro-
2 posals for Common Fund research de-
3 scribed in section 402(b)(7) to improve the
4 research portfolio; and

5 “(iv) expand the number of collabo-
6 rative, multidisciplinary, and multi-institu-
7 tional research grants;

8 “(C) develop a summary of advances in
9 breast cancer research supported or conducted
10 by Federal agencies relevant to the diagnosis,
11 prevention, and treatment of cancer and other
12 diseases and disorders; and

13 “(D) not later than 2 years after the date
14 of the establishment of the Committee, make
15 recommendations to the Secretary—

16 “(i) regarding any appropriate
17 changes to research activities, including
18 recommendations to improve the research
19 portfolio of the National Institutes of
20 Health to ensure that scientifically-based
21 strategic planning is implemented in sup-
22 port of research priorities that impact
23 breast cancer research activities;

24 “(ii) to ensure that the activities of
25 the National Institutes of Health and other

1 Federal agencies, including the Depart-
2 ment of Defense, are free of unnecessary
3 duplication of effort;

4 “(iii) regarding public participation in
5 decisions relating to breast cancer research
6 to increase the involvement of patient ad-
7 vocacy and community organizations rep-
8 resenting a broad geographical area;

9 “(iv) on how best to disseminate in-
10 formation on breast cancer research
11 progress; and

12 “(v) on how to expand partnerships
13 between public entities, including Federal
14 agencies, and private entities to expand
15 collaborative, cross-cutting research.

16 “(3) RULE OF CONSTRUCTION.—For the pur-
17 poses of the Committee, when focusing on research
18 to evaluate environmental and genomic factors that
19 may be related to the etiology of breast cancer, noth-
20 ing in this Act shall be construed to restrict the Sec-
21 retary from including other forms of cancer, as ap-
22 propriate, when doing so may advance research in
23 breast cancer or advance research in other forms of
24 cancer.

25 “(4) MEMBERSHIP.—

1 “(A) IN GENERAL.—The Committee shall
2 be composed of the following voting members:

3 “(i) Not more than 7 voting Federal
4 representatives as follows:

5 “(I) The Director of the Centers
6 for Disease Control and Prevention.

7 “(II) The Director of the Na-
8 tional Institutes of Health and the di-
9 rectors of such national research insti-
10 tutes and national centers (which may
11 include the National Institute of Envi-
12 ronmental Health Sciences) as the
13 Secretary determines appropriate.

14 “(III) One representative from
15 the National Cancer Institute Board
16 of Scientific Advisors, appointed by
17 the Director of the National Cancer
18 Institute.

19 “(IV) The heads of such other
20 agencies of the Department of Health
21 and Human Services as the Secretary
22 determines appropriate.

23 “(V) Representatives of other
24 Federal agencies that conduct or sup-

1 port cancer research, including the
2 Department of Defense.

3 “(ii) 12 additional voting members ap-
4 pointed under subparagraph (B).

5 “(B) ADDITIONAL MEMBERS.—The Com-
6 mittee shall include additional voting members
7 appointed by the Secretary as follows:

8 “(i) 6 members shall be appointed
9 from among scientists, physicians, and
10 other health professionals, who—

11 “(I) are not officers or employees
12 of the United States;

13 “(II) represent multiple dis-
14 ciplines, including clinical, basic, and
15 public health sciences;

16 “(III) represent different geo-
17 graphical regions of the United
18 States;

19 “(IV) are from practice settings,
20 academia, or other research settings;
21 and

22 “(V) are experienced in scientific
23 peer review process.

1 “(ii) 6 members shall be appointed
2 from members of the general public, who
3 represent individuals with breast cancer.

4 “(C) NONVOTING MEMBERS.—The Com-
5 mittee shall include such nonvoting members as
6 the Secretary determines to be appropriate.

7 “(5) CHAIRPERSON.—The voting members of
8 the Committee shall select a chairperson from
9 among such members. The selection of a chairperson
10 shall be subject to the approval of the Director of
11 NIH.

12 “(6) MEETINGS.—The Committee shall meet at
13 the call of the chairperson of the Committee or upon
14 the request of the Director of NIH, but in no case
15 less often than once each year.

16 “(b) REVIEW.—The Secretary shall review the neces-
17 sity of the Committee in calendar year 2011 and, there-
18 after, at least once every 2 years.”.

19 (b) AUTHORIZATION OF APPROPRIATIONS.—For the
20 purpose of carrying out research activities under title IV
21 of the Public Health Service Act, including section 417F
22 of such Act, as added by subsection (a) there are author-
23 ized to be appropriated \$40,000,000 for each of fiscal
24 years 2009 through 2012. Amounts authorized to be ap-
25 propriated under the preceding sentence shall be in addi-

1 tion to amounts otherwise authorized to be appropriated
2 for such purpose under section 402A of the Public Health
3 Service Act (42 U.S.C. 282a).